Prostaglandin cyclooxygenase products but not thromboxane A2 are involved in the pathogenesis of ewthromelalgia in thrombocythaemia by Michiels, J. J. & Zijlstra, F. J.
Research Paper
Mediators of Inflammation 2, 373-377 (1993)
THE selective enzyme inhibitors genistein and Re 31-8220
were used to assess the importance of protein tyrosine
kinase (PTK) and protein kinase C (PKC), respectively,
in N-formyl-methionyl-leucyl-phenylalanine (FMLP) in-
duced generation of superoxide anion and thromboxane
B2 (TXB2) in guinea-pig alveolar macrophages (AM).
Genistein (3-100 pM) dose dependently inhibited FMLP
(3 nM) induced superoxide generation in non-primed AM
and TXB release in non-primed or in lipopolysaccharide
(LPS) (10 ng/ml) primedAM to a level >80% but had litle
effect up to 100uM on phorbol myristate acetate (PMA)
(10 nM) induced superoxide release. Re 31-8220 inhibited
PMA induced superoxide generation (ICs0 0.21 + 0.10 pM)
but had no effect on or potentiated (at 3 and 10/M) FMLP
responses in non-primed AM. In contrast, when present
during LPS priming as well as during FMLP challenge
Re 31-8220 (10 pM) inhibited primed TXB release by
> 80%. The results indicate thatPTK activation is required
for the generation of these inflammatory mediators by
FMLP in AM. PKC activation appears to be required for
LPS priming but not for transducing the FMLP signal;
rather, PKC activation may modulate the signal by a
negative feedback mechanism.
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Introduction
The alveolar macrophage (AM) is the most
abundant cell in the airway lumen and may be an
important contributor to the inflammation asso-
ciated with pulmonary diseases such as asthma, a’2
Isolated AM respond to a variety of immunological
and non-immunological stimuli by generating both
acute-phase and pro-inflammatory mediators. The
acute-phase mediators include the spasmogens
thromboxane A2, leukotriene C4 and platelet
activating factor (PAF) as well as reactive oxygen
species and lysosomal enzymes which can cause
local tissue damage.
3 Among the pro-inflammatory
mediators are PAF, leukotriene B4 and a number of
cytokines which are chemoattractant to mast cells,
eosinophils and lymphocytes, all of which have
been implicated in pulmonary inflammation, a’2 In
addition to being directly activated AM can be
primed in vitro by agents including LPS4 and gamma
interferon to give an exaggerated response to
subsequent stimuli. AM primed in vitro may be
comparable with AM from asthmatic subjects
which have been shown to release greater amounts
ofmany of the above mediators on stimulation than
cells from non-asthmatic subjects.
6-9
The biochemical mechanisms underlying priming
are poorly understood but may involve amplifica-
tion of signal transduction processes. For the
chemotactic peptide FMLP three receptor-coupled
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signalling pathways have been identified: (i)
G-protein linked phospholipase C (PLC) which
generates inositol 1,4,5 trisphosphate and dia-
cylglycerol (DAG) from phosphoinositides,a (ii)
phospholipase D generation of DAG from
phosphatidyl choline,
al and (iii) activation of
non-receptor PTK. a2’13 As PTK can activate PLCy
4
to generate DAG, activation of PKC could
represent a common end point for all of these
pathways, although other mechanisms of PTK
dependent cell activation clearly exist. Both PKC
and PTK have been implicated in the priming
process in macrophages; for instance in murine
peritoneal macrophages LPS priming stimulated
myristoylation and translocation of an intracellular
substrate for PKC thus improving the efficiency of
this signal transduction pathway,as whilst LPS
priming in P388 D1 cells was shown to require
protein synthesis and to be blocked by a PTK
inhibitor, a6
In order to investigate the importance of PTK
and PKC enzyme systems in FMLP activation of
AM we have studied the effects of the selective PTK
inhibitor genistein
7 and the selective PKC inhibitor
Re 31-822018 on superoxide and TXB2 (as a marker
for arachidonate metabolism) generation in normal
cells, and on TXB2 generation in LPS primed cells.
As a control measure the effects of these compounds
on superoxide release induced by FMLP were
compared with those on superoxide release induced
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by the phorbol ester PMA, which is known to act
by stimulating PKC directly.
Materials and Methods
Male Dunkin-Hartley guinea-pigs were pur-
chased from David Hall, Burton-on-Trent, UK.
Tissue culture reagents were obtained from
Gibco; FMLP, phorbol myristate acetate (PMA),
type II1 cytochrome c, LPS (E. coli 055:B5) and
superoxide dismutase from Sigma, UK; and TXB2
radioimmunoassay kits from Amersham, UK.
Protein was determined after disruption of cells
with 0.1% Triton X-100 using BioRad Coomassie
blue reagent. Genistein was purchased from
ICN-Flow whilst Ro 31-8220 was synthesized at
Dagenham Research Centre. Compounds were
initially dissolved in dimethylsulphoxide (DMSO)
and diluted in Hank’s balanced salt solution (HBSS)
to a final DMSO concentration in cell incubates of
<_ 0.1% v/v.
Preparation of AM: Male guinea-pigs (400-600 g)
were killed by intraperitoneal administration of
sodium pentobarbitone, the trachea cannulated and
bronchoalveolar lavage carried out with two 5 ml
volumes of saline at 37C. Lavage fluid was
centrifuged at 300 x g" for 8 min, cells resuspended
in Ca2+ and Mg
2+ free HBSS and pooled. The cell
suspension was centrifuged again and cells
resuspended at 106 cells/ml in RPMI 1640 medium
supplemented with 1% foetal calf serum, 50 U/ml
penicillin and 50 #g/ml streptomycin. For super-
oxide experiments cells were plated out in 24-well
dishes at 106 cells/well; for TXB2 experiments in
96-well dishes at 2 x 105 cells/well. After 2 h in an
incubator (37C, 5% COg) non-adherent cells and
debris were removed by changing the medium.
AdherentAM were left in the incubator for 18-20 h
before use.
Measurement of superoxide production: Tissue culture
medium was removed, AM washed once with
HBSS then HBSS (0.5ml) with or without
inhibitors was added and the cells incubated at 37C
for 2 h. Buffer was then replaced by fresh HBSS
(0.5 ml) containing Fe3+ cytochrome c (55/iM),
again with or without inhibitors. After 15 min at
37C FMLP or PMA was added and the incubation
continued for a further 30 min. Superoxide
generation was determined from the difference in
absorbance of the AM supernatants at 550 nm in
comparison with supernatants from cells stimulated
in the presence of superoxide dismutase (0.1
mg/ml).
19 Using this protocol the absorbance
difference was directly proportional to superoxide
concentration.
Measurement of TXBe release" After removal of tissue
culture medium AM were washed once with HBSS
then incubated for 2 h at 37C in HBSS (0.2 ml)
with or without inhibitors and with or without LPS
(10 ng/ml) for cell priming. The buffer was replaced
by fresh HBSS (0.2 ml) again with or without
inhibitors, and the incubation continued for 15 min
prior to adding FMLP for a further 15 min.
Supernatants removed at appropriate times were
stored at -20C prior to quantification of TXB2
by radioimmunoassay. Samples were diluted to fall
within the assay standard curve; concentrations
were calculated by interpolation using a Multi Calc
software program (Wallac, Finland).
Statistics" Superoxide and TXB2 concentrations were
calculated as mean --t-_ S.E.M. of triplicate or
quadruplicate determinations within each experi-
ment. Since the magnitude of stimulated release
varied with different preparations of cells, in all
cases the figures show values from one representa-
tive experiment which was conducted 2-4 times.
ICs0 values and other data in the Results section are
expressed as mean _+S.E.M. from the stated
number of replicate experiments.
Results
Effects on superoxide generation" Adherent guinea-pig
AM prepared as described showed a very low basal
generation of superoxide (<_ 0.1 nmole/assay). Both
FMLP and PMA (0.3-30 nM) caused concentration
dependent stimulation of superoxide generation
with EC50 values of 1.2, 2.6 nM and 3.0, 5.4 nM,
respectively, in two experiments and similar
maximal stimulation (1-2 nmoles/assay). The effects
of genistein and Ro 31-8220 were evaluated against
sub-maximal (approx. ECT0) agonist concentrations
(3nM FMLP, 10nM PMA) that gave similar
responses (compare Figs 1A and 1B). Consistent
with its activity as a PKC antagonist Ro 31-8220
inhibitedPMA induced superoxide generation (Fig.
1A); in three experiments the 1C50 was 0.21 0.10
#M. Whereas genistein at concentrations up to
100/iM had little effect on the PMA response it
dose-dependently inhibited FMLP induced super-
oxide generation (Fig. 1B); in four experiments the
ICs0 was 54_--k 9/iM. Ro 31-8220 at low
concentrations (0.1-1 #M) had little or no in-
hibitory effect on the FMLP response whereas at
higher concentrations (3 and 10 #M) it consistently
enhanced the FMLP response (by 64 +_ 16% at
10 #M; n 3 experiments).
At the highest concentrations employed Ro
31-8220 and genistein did not reduce cell viability
as assessed by trypan blue dye exclusion, viability
being consistently _> 95%.
Effects on TXBe release" Pre-incubation of guinea-pig
AM for 2 h with LPS (10 ng/ml) in itself caused
some increase in TXB2 release from a basal level of
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FIG. 1. The effects of Ro 31-8220 and genistein on PMA (Panel A) or
FMLP (Panel B) induced superoxide release from non-primed guinea-pig
AM. AM (10S/well) were incubated with or without inhibitors for 2.25 h
at 37C prior to addition of stimulus for 30 min. Superoxide was
determined by superoxide dismutase inhibitable reduction of Fe3+
cytochrome c. Mean-t-S.E.M. (n= 3) from a single representative
experiment.
0.10 _---t- 0.01 to 1.0 +_ 0.2ng/10/g AM protein
(n 4 experiments). However LPS potentiated
markedly (primed) the response to FMLP over the
full concentration range tested (0.3-30 nM) (Fig. 2).
FMLP (3 nM), as a non-maximal stimulus, was used
to study the eEects of Ro 31-8220 and genistein on
TXB2 release.
When present during the 2 h pre-incubation, or
2h LPS priming, stage and the subsequent
challenge stage genistein (1-30/M) dose-depen-
dently inhibited FMLP stimulated TXB2 release in
both non-primed and primed AM with similar ICs0
values (17 and 18#M, respectively, in the
experiment shown in Fig. 3A). Under these
conditions Ro 31-8220 (0.1-10/,M) did not inhibit
FMLP induced TXB2 release in non-primed AM
but tended rather to potentiate release at higher
concentrations (by >27% at 3 and 10 #M in the
experiment shown) (Fig. 3B). The extent of
potentiation varied between experiments but was a
consistent observation. In LPS primed AM low
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FIG. 2. Demonstration of LPS priming of AM for TXB2 release induced by
FMLP. AM (2 x 10S/well) were incubated in HBSS or in HBSS containing
LPS (10 ng/ml) for 2 h at 37C then the medium replaced by fresh HBSS.
After 15 min at 37C FMLP was added for a further 15 min. TXB2 was
measured by RIA. Mean __. S.E.M. (n 4) from a single representative
experiment.., Non-primed" I--I, primed.
concentrations of Ro 31-8220 (0.1-3 #M) had no
effect on the FMLP response whereas Ro 31-8220
at 10/,M inhibited TXB. release by 80% relative to
the LPS baseline level. Since this suggested that Ro
31-8220 had an inhibitory effect on a component of
LPS priming, further studies were performed in
which Ro 31-8220 (10M) was added to the AM
only during selected stages of priming and/or
activation (Fig. 4). Ro 31-8220 had no effect on the
LPS primed response when present only during
FMLP challenge, inhibited the response by approx.
50% when present only during priming, but had
greatest effect, reducing FMLP induced TXB2
release by 80 and 100% in relation to the LPS
baseline value (n--2 experiments), when present
during both priming and challenge. The essential
requirement for inhibition was thus that Ro 31-8220
was present during the LPS priming stage.
Discussion
Ro 31-8220 and genistein were used in the present
study as selective inhibitors of PKC and PTK,
respectively. Ro 31-8220 is reported to have a
100-fold selectivity for PKC over protein kinase A
(PKA) and a 1 000-fold selectivity over Ca2+-cal
modulin dependent kinase
18 and has been used by
several groups as a selective PKC inhibitor in intact
cells.
2-22 Genistein inhibits a number of PTKs but
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FIG. 3. The effects of genistein (Panel A) or Ro 31-8220 (Panel B) on FMLP
induced TXB2 release from non-primed or LPS-primed AM. AM were
primed with LPS (10 ng/ml) and stimulated with FMLP (3 nM) as described
in the legend to Fig. 2. Genistein or Ro 31-8220 were added during both
LPS priming and FMLP stimulation. Mean -!- S.E.M. (n 4) from a single
representative experiment. I-3, Non-primed;., primed.
FIG. 4. Influence of the stage of LPS priming, or FMLP challenge at which
Ro 31-8220 was added, on its ability to inhibit TXB2 release. AM were
primed with LPS (10 ng/ml) and stimulated with FMLP (3 nM) as described
in the legend to Fig. 2. LPS -I- (Ro -I- FMLP)" Ro 31-8220 added for 15 min
prior to, and during FMLP stimulation, but not during priming"
(Ro -t- LPS) -t- FMLP" Ro 31-8220 added during LPS priming but removed
before FMLP stimulation" (Ro + LPS) + (Ro + FMLP)" Ro 31-8220 added
during LPS priming and for 15 min prior to, and during, FMLP stimulation.
Mean -I- S.E.M. (n 4) from a single representative experiment.
shows very weak activity against serine and
threonine kinases including PKC, PKA and
phosphorylase kinase. 17 At the concentrations
employed neither Ro 31-8220 nor genistein reduced
AM viability, thus ruling out nonspecific cytotoxi-
city as an explanation of any observed effects of the
compounds.
The finding that Ro 31-8220 inhibited PMA
induced superoxide generation but not FMLP
induced superoxide generation or TXB2 release in
non-primed AM indicates that PKC either does not
transduce the FMLP signal or that it has feed back
as well as feed forward et:fects on signal
transduction. The fact that Ro 31-8220 consistently
increased superoxide or TXB2 release (albeit not
markedly) rather than merely being without eect
on release leads us to favour the latter explanation.
There is increasing evidence from a number of cell
types that PKC inhibition can increase cellular
activation, apparently by blocking inhibitory eects
of PKC on phospholipase C. For instance, Ro
31-8220 was shown to potentiate PAF stimulated
TXB2 release from platelets,
2 IgE stimulated
histamine release from human basophils,
23 and
zymosan induced phospholipase C activity in liver
macrophages.
1 In addition, in the latter study the
activation of phospholipase C by zymosan was
enhanced by chronic pretreatment of the macro-
phages with PMA to down-regulate PKC. It is
unlikely that a Ro 31-8220 insensitive isoform of
PKC was involved in FMLP stimulated superoxide
and TXB2 production in the AM studied in the
present work since Ro 31-8220 is not isozyme
selective and, in addition, the compound inhibited
the superoxide response to PMA.
In contrast to the complex activity ofRo 31-8220,
the consistent inhibitory effects of genistein on
FMLP responses in both non-primed and primed
AM support only a proactive role for a PTK in
FMLP stimulus-response coupling in AM, as has
recently been reported for neutrophils2’24 and for
HL-60 cells. 13 Whether the pathways leading to
superoxide or TXB2 release are separately regulated
by PTK or whether PTK action affects an early
common event such as PLCy activation,
4 or PLD
activation,
is each of which has been demonstrated
in other cell types, remains to be determined.
Nonetheless, the ability of genistein to inhibit
superoxide production and TXB2 release almost
completely emphasizes the key importance of PTK
activation following FMLP receptor stimulation.
The observation that Ro 31-8220 was able to
inhibit FMLP induced TXB2 production in primed
AM provided that the compound was present
during the priming event is of interest in
demonstrating that LPS induces priming by a
process which is positively regulated by PKC. This
does not appear surprising in view of other reports
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that LPS can activate PKC in macrophages
26 and
that responses to LPS such as cytokine production
are blocked by PKC inhibitors.27 It does, however,
differ from findings in P388 D1 macrophages where
the non-selective PKC inhibitor H7 did not affect
cell priming.
16 The fact that Ro 31-8220 present
during FMLP challenge as well as during priming
increased the inhibition of TXB2 release contrasts
with the potentiation of release seen in non-primed
AM and probably reflects the complex interplay
between feed forward and feed back effects of PKC
on mediator release in these cells.
In summary, using selective enzyme inhibitors it
was found that activation of PTK is a key event in
FMLP generation of superoxide and TXB2 in
guinea-pigAM whereas PKC either is not activated,
or is activated but has counter-balancing feed back
and feed forward effects on mediator release in
non-primed cells. On the other hand activation of
PKC appears to be required for LPS priming of
these cells for enhanced TXB2 release. Thus both
PTK and PKC inhibitors could conceivably be
effective in reducing the release of these mediators
from macrophages in the airways in vivo under
conditions where priming has occurred during an
inflammatory response.
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